Search

Your search keyword '"Coebergh, J. W. W."' showing total 25 results
Start Over Author "Coebergh, J. W. W." Topic cancer

Refine your results

25 results on '"Coebergh, J. W. W."'

5. The advantage of women in cancer survival: An analysis of EUROCARE-4 data

Author

Micheli, A., Ciampichini, R., Oberaigner, W., Ciccolallo, L., de Vries, E., Izarzugaza, I., Zambon, P., Gatta, G., De Angelis, R., Hackl, M., Van Eycken, E., Verstreken, Martine, Holub, J., Jurickova, L., Storm, H. H., Engholm, G., Hakulinen, T., Belot, A., Hedelin, G., Velten, M., Tron, I., Le Gall, E., Launoy, G., Guizard, A. V., Faivre, J., Bouvier, A. M., Carli, P. M., Maynadie, M., Danzon, A., Buemi, A., Tretarre, B., Lacour, B., Desandes, E., Colonna, M., Molinie, F., Bara, S., Schvartz, C., Ganry, O., Grosclaude, P., Brenner, H., Kaatsch, P., Ziegler, H., Tryggvadottir, L., Comber, H., Berrino, F., Allemani, C., Baili, P., Sant, M., Sowe, S., Zigon, G., Tagliabue, G., Contiero, P., Bellu`, F., Giacomin, A., Ferretti, S., Serraino, D., Dal Maso, L., De Dottori, M., D. e. Paoli, A., Zanier, L., Vercelli, M., Orengo, M. A., Casella, C., Quaglia, A., Pannelli, F., Federico, M., Rashid, I., Cirilli, C., Fusco, M., Traina, A., De Lisi, V., Bozzani, F., Magnani, C., Pastore, G., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Mangone, L., Falcini, F., Foca, F., Giorgetti, S., Senatore, G., Iannelli, A., Budroni, M., Patriarca, S., Zanetti, R., Rosso, S., Piffer, S., Franchini, S., Paci, E., Crocetti, E., La Rosa, F., Stracci, F., Cassetti, T., Guzzinati, S., Caldora, M., Capocaccia, R., Carrani, E., Francisci, S., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Dalmas, M., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Gozdz, S., Siudowska, U., Mezyk, R., Bielska-Lasota, M., Zwierko, M., Pinheiro, P. S., Primic-Zakelj, M., Mateos, A., Torrella-Ramos, A., Zurriaga, Oscar, Marcos-Gragera, R., Vilardell, M. L., Izquierdo, A., Martinez-Garcia, C., Sanchez, M. J., Navarro, C., Chirlaque, M. D., Peris-Bonet, R., Ardanaz, E., Moreno, C., Galceran, J., Klint, A., Talback, M., Jundt, G., Usel, M., Frick, H., Ess, S. M., Bordoni, A., Luthi, J. C., Konzelmann, I., Probst, N., Lutz, J. M., Pury, P., Visser, O., Otter, R., Schaapveld, M., Coebergh, J. W. W., Janssen-Heijnen, M. L., Louis van der Heijden, Null, Greenberg, D. C., Coleman, M. P., Woods, Laura, Moran, T., Forman, D., Cooper, N., Roche, M., Verne, J., Mã¸ller, H., Meechan, D., Poole, J., Lawrence, G., Stiller, C., Gavin, A., Black, R. J., Brewster, D. H., Steward, J. A., Basque Country Cancer Registry, Vitoria-Gasteiz, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), and Public Health

Subjects
Oncology, Male, Pathology, Cancer Research, cancer survival - women, MESH : Age Distribution, MESH : Aged, MESH: Risk Assessment, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, MESH: Aged, 80 and over, Residence Characteristics, Neoplasms, 80 and over, Gender differences, Sex hormones, MESH: Neoplasms, MESH : Female, MESH: Residence Characteristics, Young adult, Age of Onset, MESH : Risk Assessment, MESH : Sex Distribution, MESH: Diagnosis-Related Groups, MESH: Aged, Aged, 80 and over, 0303 health sciences, education.field_of_study, MESH: Middle Aged, Relative survival, Thyroid, MESH: Sex Distribution, Middle Aged, MESH : Adult, 3. Good health, MESH : Age of Onset, Europe, MESH : Diagnosis-Related Groups, medicine.anatomical_structure, MESH: Young Adult, 030220 oncology & carcinogenesis, MESH: Survival Analysis, MESH : Residence Characteristics, Female, EUROCARE, Adult, medicine.medical_specialty, Adolescent, MESH: Age of Onset, MESH : Male, MESH : Sex Factors, Population, MESH : Europe, MESH : Young Adult, Rectum, Socio-culturale, [SDV.CAN]Life Sciences [q-bio]/Cancer, Risk Assessment, 03 medical and health sciences, Young Adult, Age Distribution, Sex Factors, MESH: Sex Factors, SDG 3 - Good Health and Well-being, Internal medicine, MESH : Adolescent, medicine, Humans, MESH : Middle Aged, Sex Distribution, education, MESH : Aged, 80 and over, MESH: Age Distribution, Survival analysis, Diagnosis-Related Groups, 030304 developmental biology, Aged, MESH: Adolescent, MESH: Humans, business.industry, MESH : Humans, Cancer, Cancer survival, Survival Analysis, MESH: Adult, medicine.disease, MESH : Neoplasms, MESH: Male, MESH: Europe, Age of onset, MESH : Survival Analysis, business, MESH: Female
Abstract

We analysed 1.6 million population-based EUROCARE-4 cancer cases (26 cancer sites, excluding sex-specific sites, and breast) from 23 countries to investigate the role of sex in cancer survival according to age at diagnosis, site, and European region. For 15 sites (salivary glands, head and neck, oesophagus, stomach, colon and rectum, pancreas, lung, pleura, bone, melanoma of skin, kidney, brain, thyroid, Hodgkin disease and non-Hodgkin's lymphoma) age- and region-adjusted relative survival was significantly higher in women than men. By multivariable analysis, women had significantly lower relative excess risk (RER) of death for the sites listed above plus multiple myeloma. Women significantly had higher RER of death for biliary tract, bladder and leukaemia. For all cancers combined women had a significant 5% lower RER of death. Age at diagnosis was the main determinant of the women's advantage, which, however, decreased with increasing age, becoming negligible in the elderly, suggesting that sex hormone patterns may have a role in women's superior ability to cope with cancer. (C) 2008 Elsevier Ltd. All rights reserved.

Published
2009

6. Childhood cancer survival in Europe

Author

Gatta, G., Corazziari, I., Magnani, C., Peris Bonet, R., Roazzi, P., Stiller, C., Oberaigner, W., Jechova, M., Rousarova, M., Storm, H. H., Aareleid, T., Hakulinen, T., Hédelin, G., Tron, I., Le Gall, E., Launoy, G., Macé Lesech, I., Faivre, I., Chaplain, G., Carli, P. M., Lacour, B., Raverdy, N., Berger, C., Freycon, F., Grosclaude, P., Estève, I., Kaatsch, P., Tryggvadottir, L., Berrino, F., Allemani, C., Baili, P., Ciccolallo, L., Micheli, A., Sant, M., Taussig, E., Capocaccia, R., Carrani, E., De Angelis, R., Hartley, S., Santaquilani, M., Tavilla, A., Valente, F., Verdecchia, A., Ferretti, S., Crosignani, P., Tagliabue, G., Conti, E., Vercelli, M., Pannelli, F., Mosciatti, P., Federico, Massimo, Artioli, M. E., De Lisi, V., Serventi, L., Pastore, G., Gafà, L., Tumino, R., Falcini, F., Budroni, M., Paci, E., Crocetti, E., Zambon, P., Guzzinati, S., Dalmas, M., Langmark, F., Andersen, A, Rachtan, J., Bielska Lasota, M., Wronkowski, Z., Zwierko, M., Pleško, I., Obsitníková, A., Pompe Kirn, V., Izarzugaza, I., Martinez Garcia, C., Garau, I., Navarro, C., Chirlaque, M. D., Ardanaz, E., Moreno, C., Galceran, J., Torrella, A., Barlow, L., Möller, T., Lutz, J. M., Usel, M., Coebergh, J. W. W., Van Der Does Van Den Berg, A., Visser, O., Coleman, M. P., Black, R., and Brewster, D.

Subjects
Male, Pediatrics, medicine.medical_specialty, Adolescent, Population, Disease, Malignancy, Childhood Cancer Survival Trends, Neoplasms, medicine, Humans, Child, education, education.field_of_study, business.industry, Incidence (epidemiology), Gold standard, Age Factors, Cancer, Hematology, medicine.disease, Survival Analysis, Childhood tumours, Europe, Population-based study, Survival variation, Lymphoma, Europe, Survival Rate, Oncology, Child, Preschool, Female, Major Diagnostic Category, business
Abstract

BACKGROUND: EUROCARE-3 collected data from 45 population-based cancer registries in 20 countries on 24 620 European children aged from 0 to 14 years diagnosed with malignancy in the period 1990-1994. METHODS: Five-year survival between countries was compared for all malignancies and for the major diagnostic categories, adjusting for age, and estimated average European survival weighting for differences in childhood populations. RESULTS: For all cancers combined, survival variation was large (45% in Estonia to 90% in Iceland), and was generally low (60-70%) in eastern Europe and high (> or =75%) in Switzerland, Germany and the Nordic countries (except Denmark). The Nordic countries had the highest survival for four of the seven major tumour types: nephroblastoma (92%), acute lymphoid leukaemia (85%), CNS tumours (73%) and acute non-lymphocytic leukaemia (62%). The eastern countries had lowest survival: 89% for Hodgkin's disease, 71% for nephroblastoma, 68% for acute lymphoid leukaemia, 61% for non-Hodgkin's lymphoma, 57% for central nervous system (CNS) tumours and 29% for acute non-lymphocytic leukaemia. CONCLUSIONS: The Nordic countries represent a survival gold standard to which other countries can aspire. Since most childhood cancers respond well to treatment, survival differences are attributable to differences in access (including referral and timely diagnosis) and use of modern treatments; however, the obstacles to access and application of standard treatments probably vary markedly with country.

Published
2003

7. EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century

Author

Coleman, M. P., Gatta, G., Verdecchia, A., Estève, J., Sant, M., Storm, H., Allemani, C., Ciccolallo, L., Santaquilani, M., Berrino, F., Oberaigner, W., Jechova, M., Rousarova, M., Storm, H. H., Aareleid, T., Hakulinen, T., Hédelin, G., Tron, I., Le Gall, E., Launoy, G., Macé Lesec'h, J., Faivre, J., Chaplain, G., Carl, P. M., Danzon, A., Tretarre, B., Colonna, M., Lacour, B., Raverdy, N., Berger, C., Freycon, F., Grosclaude, P., Estèv, Z, Kaatsch, P., Ziegler, H., Hölzel, D., Schubert Fritschle, G., Tryggvadottir, L., Baili, P., Micheli, A., Taussig, E., Capocaccia, R., Carrani, E., De Angelis, R., Hartley, S., Roazzi, P., Tavilla, A., Valente, F., Ferretti, S., Crosignani, P., Contiero, P., Conti, E., Vercelli, M., Pannelli, F., Vitarelli, S., Mosciatti, P., Federico, Massimo, Artioli, M. E., PONZ DE LEON, Maurizio, Benatti, Piero, De Lisi, V., Serventi, L., Zanetti, R., Patriarca, S., Magnani, C., Pastore, G., Gafà, L., Tumino, R., Falcini, F., Budroni, M., Paci, E., Crocetti, E., Zambon, P. Guzzinati S., Dalmas, M., Langmark, F., Andersen, A., Rachtan, J., Bielska Lasota, M., Wronkowski, Z., Zwierko, M., Pinheiro, P. S., Pleško, I., Obsitníková, A., Pompe Kirn, V., Izarzugaza, I., Martinez Garcia, C., Garau, I., Navarro, C., Chirlaque, M. D., Ardanaz, E., Moreno, C., Galceran, J., Torrella, A., Peris Bonet, R., Barlow, L., Möller, T., Jundt, G. Lutz J. M., Usel, M., Coebergh, J. W. W., Van Der Does Van Den Berg, A., Visser, O., Godward, S., Williams, E. M. I., Forman, D., Quinn, M. J., Roche, M., Edwards, S., Stiller, C., Verne, J., Møller, H., Bell, J., Botha, J. L., Lawrence, G., Black, R., Brewster, D., Steward, J. A., Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Male, [SDV.OT]Life Sciences [q-bio]/Other [q-bio.OT], Pathology, medicine.medical_specialty, population-based cancer registries, Lung Neoplasms, Skin Neoplasms, Population, Uterine Cervical Neoplasms, Breast Neoplasms, Disease, Sex Factors, Testicular Neoplasms, Stomach Neoplasms, Neoplasms, Epidemiology, Health care, Humans, Medicine, Registries, cancer survival, Child, education, Survival rate, Survival analysis, education.field_of_study, business.industry, Age Factors, international comparison, Prostatic Neoplasms, Cancer, Hematology, medicine.disease, Survival Analysis, Cancer survival, Europe, Survival Rate, Oncology, Colonic Neoplasms, Female, Observational study, business, Demography
Abstract

Summary International differences and trends in cancer survival withinEurope are larger than can reasonably be accounted for by arte-fact, bias or chance. The geographical patterns and trends in sur-vival are often broadly consistent with geographical differences ortrends in the type of cancer, diagnostic investigations or overallinvestment in health care, and for several major cancers, support-ing evidence is available from population-based studies of clinicalinformation. Incomplete ascertainment of cancer cases, particu-larly of long-term survivors, may contribute to some regional andinternational differences in survival, however, and more system-atic information on completeness is required. We may concludethat large international differences in survival do exist for manycancers, but we should be cautious in drawing quantitative orcausal conclusions from observational survival data.We do not yet have a fully satisfactory interpretation of thesedifferences, but we have few alternatives to this type of study if weare to understand the determinants of improved outcome for allcancer patients, and to enable better planning of their health care.The EUROCARE Working Group has developed several strategiesto disentangle the various possible explanations [73]. These includefurther development of high-resolution studies to examine theimpact on survival differences of disease stage, staging techniquesand treatment; and further development of mathematical modelsof cure. Extension of systematic international survival compari-sons to other regions of the world, such as Australia, Canada, Japanand the USA, is also in progress (the CONCORD study) [22].Oncologists and epidemiologists may provide insight into thegeographic differences and trends in survival reported by thisstudy, and may suggest further lines of enquiry. Do we need morerefined studies of survival to monitor progress against cancer andto plan future cancer care? Will such analyses help us quantify theeffect of new treatments arising from recent progress in the basicsciences and genomics on population cancer survival rates? Sub-stantial human and financial resources are required to improve theoutcome of cancer treatment. Will future investments in cancerservices include matching investment to monitor their impact onsurvival and mortality?Earlier diagnosis and prompt, universal access to optimal treat-ment would be expected to reduce international differences incancer survival in Europe. To achieve this, oncologists and healthcare planners will need better information on the comparativeperformance of their health systems. Population-based cancer reg-istries provide some of the information for such comparisons, buttheir traditional output may no longer be sufficient to evaluate theeffectiveness of health systems, and especially to explain geo-graphical differences in survival. In some countries, their role isalso under threat. Confidentiality constraints recently inhibitedthe collection of cancer registration data in the UK [90], and thelinkage of cancer registrations and deaths is currently illegal inEstonia [91]. Both activities are essential for internationally com-parable survival rates. Legal protection for cancer registrationacross Europe will be required.The mission of cancer registries should be reconsidered, and thepriority shifted from classical descriptive epidemiology and geo-graphical pathology toward more analytical monitoring ofprogress against cancer, including the probability of survival andcure, the burden of cancer prevalence, and the late effects oftherapy. Several European studies of this type have been reportedrecently [3, 36, 9294] and others are in progress. Many cancer–registries are developing closer relationships with cancer clini-cians and general practitioners, and some now systematicallycollect detailed clinical information that was collected eitherirregularly or not at all in the past. These developments willimprove the power of population-based cancer data to explain dif-ferences in cancer survival, and should enhance their relevance toclinical practice.European average survival rates are useful for comparativepurposes, but they should not become the goal for cancer controlprogrammes: the benchmark should always be the highest achiev-able survival rates.The aim of exploring geographic differences in cancer survivalis not to establish international league tables or to excite nationalrivalries, but to estimate the range of survival rates, and to identifyregions or countries in which survival could be improved.

Published
2003

8. Descriptive epidemiology of Kaposi sarcoma in Europe. Report from the RARECARE project

Author

Stiller, C. A, Trama, A., Brewster, D. H., Verne, J., Bouchardy, C., Navarro, C., Chirlaque, M. D., Marcos Gragera, R., Visser, O., Serraino, D., Weiderpass, E., Dei Tos, A. P., Ascoli, V., Zielonk, N., Van Eycken, E., Sundseth, H., Hedelin, G., Bouvier, A. M., Woronoff, A. S., Buemi, A., Tretarre, B., Colonna, M., Bara, S., Ganry, O., Grosclaude, P., Baconnier, S., Holleczek, B., Geissler, J., Wartenberg, M., Tryggvadottir, L., Deady, S., Bellu, F., Ferretti, Stefano, Vercelli, M., Vitarelli, S., Federico, M., Fusco, M., Michiara, M., Giacomin, A., Tumino, R., Mangone, L., Falcini, F., Senatore, G., Budroni, M., Piffer, S., Crocetti, E., La Rosa, F., Tagliabue, G., Zambon, P., Gatta, G., Gronchi, A., Licitra, L., Ruzza, M., Sowe, S., Capocaccia, R., De Angelis, R., Mallone, S., Tavilla, A., England, K., Ursin, G., Rachtan, J., Gozdz, S., Zwierko, M., Bielska Lasota, M., Slowinski, J., Miranda, A., Safaei Diba, C., Primic Zakelj, M., Mateos, A., Bidaurrazaga, J., Torrella Ramos, A., Ardanaz, E., Galceran, J., Martinez Garcia, C., Sanchez Perez, M. J., Melchor, J. M., Adolfsson, J., Lambe, M., Möller, T. R., Ringborg, U., Jundt, G., Usel, M., Ess, S. M., Spitale, A., Konzelmann, I., Lutz, J. M., Coebergh, J. W. W., Otter, R., Siesling, S., van der Zwan, J. M., Schouten, H., Greenberg, D. C., Wilkinson, J., Roche, M., Meechan, D., Lawrence, G., Mackay, J., Gavin, A., Kunkler, I., and White, C.

Subjects
Adult, Male, Pediatrics, medicine.medical_specialty, Cancer Research, Survival, Epidemiology, Population, Socio-culturale, Kaposi, Bone Sarcoma, Acquired immunodeficiency syndrome (AIDS), medicine, Prevalence, Humans, Rare cancers, education, Sarcoma, Kaposi, ddc:613, Aged, Population-based study, education.field_of_study, Europe, Incidence, Kaposi sarcoma, Female, Middle Aged, Survival Analysis, Oncology, Medicine (all), Classic Kaposi Sarcoma, Relative survival, business.industry, Incidence (epidemiology), Cancer, Sarcoma, medicine.disease, Surgery, business
Abstract

Kaposi sarcoma (KS) is a virus-related malignancy which most frequently arises in skin, though visceral sites can also be involved. Infection with Kaposi sarcoma herpes virus (KSHV or HHV-8) is required for development of KS. Nowadays, most cases worldwide occur in persons who are immunosuppressed, usually because of HIV infection or as a result of therapy to combat rejection of a transplanted organ, but classic Kaposi sarcoma is predominantly a disease of the elderly without apparent immunosuppression. We analyzed 2667 KS incident cases diagnosed during 1995-2002 and registered by 75 population-based European cancer registries contributing to the RARECARE project. Total crude and age-standardized incidence rate was 0.3 per 100,000 per year with an estimated 1642 new cases per year in the EU27 countries. Age-standardized incidence rate was 0.8 per 100,000 in Southern Europe but below 0.3 per 100,000 in all other regions. The elevated rate in southern Europe was attributable to a combination of classic Kaposi sarcoma in some Mediterranean countries and the relatively high incidence of AIDS in several countries. Five-year relative survival for 2000-2002 by the period method was 75%. More than 10,000 persons were estimated to be alive in Europe at the beginning of 2008 with a past diagnosis of KS. The aetiological link with suppressed immunity means that many people alive following diagnosis of KS suffer comorbidity from a pre-existing condition. While KS is a rare cancer, it has a relatively good prognosis and so the number of people affected by it is quite large. Thus it provides a notable example of the importance of networking in diagnosis, therapy and research for rare cancers.

Published
2014

9. Rare neuroendocrine tumours: Results of the surveillance of rare cancers in Europe project

Author

Van Der Zwan, Jan Maarten, Trama, Annalisa, Otter, Renã©e, Larraã±aga, Nerea, Tavilla, Andrea, Marcos-gragera, Rafael, Dei Tos, Angelo Paolo, Baudin, Eric, Poston, Graeme, Links, Thera, Zielonke, N., Van Eycken, E., Sundseth, H., Hedelin, G., Faivre, JULIEN YVES STEPHAN, Woronoff, A. S., Buemi, A., Tretarre, B., Colonna, Marco, Bara, S., Ganry, O., Grosclaude, P., Holleczek, B., Geissler, J., Tryggvadottir, L., Deady, S., Bellã¹, F., Ferretti, Silvia, Serraino, D., Vercelli, M., Vitarelli, S., Cirilli, C., Fusco, M., Traina, Angelo, Michiara, M., Giacomin, A., Tumino, R., Mangone, L., Falcini, F., Senatore, G., Budroni, M., Piffer, S., Crocetti, E., LA ROSA, FEDERICA IRENE, Contiero, P., Fiore, A., Gatta, G., Casali, P. G., Gronchi, A., Ruzza, Marta, Sowe, S., De Angelis, R., Dei Tos, A. P., England, K., Ursin, G., Rachtan, J., Gozdz, S., Zwierko, M., Slowinski, J., Miranda, A., Safaei Diba, C., Primic-zakelj, M., Mateos, A., Martã­nez, R., Torrella-ramos, A., Osca-gelis, G., Chirlaque, M. D., Moreno, C., Galceran, J., Martinez-garcia, C., Melchor, J. M., Sã¡nchez, M. J., Virizuela-echaburu, J. A., Cervantes, A., Adolfsson, J., Lambe, M., Mã¶ller, T. R., Ringborg, U., Jundt, G., Bouchardy, C., Ess, S. M., Bordoni, A., Konzelmann, I., Lutz, J. M., Visser, O., Siesling, S., Coebergh, J. W. W., Greenberg, D. C., Wilkinson, Robert John Duncan, Roche, M., Verne, J., Meechan, D., Lawrence, G., Coleman, M. P., Mackay, J., Gavin, A., Brewster, D. H., Kunkler, I., White, C., Damage and Repair in Cancer Development and Cancer Treatment (DARE), Guided Treatment in Optimal Selected Cancer Patients (GUTS), and Bouchardy Magnin, Christine

Subjects
Male, Pediatrics, Pathology, Cancer Research, MEDULLARY-THYROID CARCINOMA, Survival, Rare Diseases/epidemiology/mortality, Neuroendocrine Tumors/epidemiology/mortality, PROGNOSTIC-FACTORS, MERKEL CELL-CARCINOMA, Prevalence, EPIDEMIOLOGY, Cancer registry, Incidence, Prevalence, Survival, Neuroendocrine, Registries, Child, education.field_of_study, Relative survival, Merkel cell carcinoma, Incidence (epidemiology), Incidence, Middle Aged, Cancer registry, Europe, Neuroendocrine Tumors, Neuroendocrine, Oncology, Child, Preschool, Epidemiological Monitoring, Female, Adult, medicine.medical_specialty, Adolescent, Population, UNITED-STATES, DIAGNOSIS, Europe/epidemiology, NO, PERIOD ANALYSIS, Young Adult, Rare Diseases, Carcinoma, medicine, Rare neuroendocrine tumours, Humans, education, Survival analysis, ddc:613, Aged, business.industry, Infant, Newborn, Cancer, Infant, NATURAL-HISTORY, medicine.disease, Survival Analysis, STAGING-SYSTEMS, business
Abstract

Because of the low incidence, and limited opportunities for large patient volume experiences, there are very few relevant studies of neuroendocrine tumours (NETs).A large population-based database (including cancer patients diagnosed from 1978 to 2002 and registered in 76 population-based cancer registries [CRs]), provided by the project 'surveillance of rare cancers in Europe' (RARECARE) is used to describe the basic indicators of incidence, prevalence and survival of NETs, giving a unique overview on the burden of NETs in Europe. NETs at all cancer sites, excluding lung, were analysed in this study. In total over 20,000 incident cases of NETs were analysed and a data quality check upon specific NETs was performed. The overall incidence rate for NETs was 25/1,000,000 and was highest in patients aged 65 years and older with well differentiated endocrine carcinomas (non-functioning pancreatic and gastrointestinal) (40 per 1,000,000). We estimated that slightly more than 100,000 people were diagnosed with NETs and still alive in EU27 at the beginning of 2008. Overall, NETs had a 5 year relative survival of 50%; survival was low (12%) for poorly differentiated endocrine carcinoma, and relatively high (64%) for well differentiated carcinoma (not functioning of the pancreas and digestive organs). Within NETs, endocrine carcinoma of thyroid gland had the best 5-year relative survival (82%).Because of the complexity and number of the different disciplines involved with NETs (as they arise in many organs), a multidisciplinary approach delivered in highly qualified reference centres and an international network between those centres is recommended. (c) 2013 Elsevier Ltd. All rights reserved.

Published
2013

10. Oesophageal cancer survival in Europe: A EUROCARE-4 study

Author

Gavin, A. T., Francisci, S., Foschi, R., Donnelly, D. W., Lemmens, V., Brenner, H., Anderson, L. A., Oberaigner, W., Hackl, M., Van Eycken, E., Henau, K., Holub, J., Jurickova, L., Storm, H. H., Engholm, G., Hakulinen, T., Belot, A., Hã©delin, G., Velten, M., Tron, I., Le Gall, E., Launoy, G., Guizard, A. V., Faivre, J., Bouvier, A. M., Carli, P. M., Maynadiã©, M., Danzon, A., Buemi, A., Tretarre, B., Lacour, B., Desandes, E., Colonna, M., Moliniã©, F., Bara, S., Schvartz, C., Ganry, O., Grosclaude, P., Kaatsch, P., Ziegler, H., Tryggvadottir, L., Comber, H., Berrino, F., Allemani, C., Baili, P., Casella, I., Margutti, C., Ciccolallo, L., Gatta, G., Micheli, A., Minicozzi, P., Sant, M., Sowe, S., Tereanu, C., Zigon, G., Tagliabue, G., Contiero, P., Bellu`, F., Giacomin, A., Ferretti, S., Serraino, D., Dal Maso, L., De Dottori, M., De Paoli, A., Zanier, L., Vercelli, M., Orengo, M. A., Casella, C., Quaglia, A., Vitarelli, S., Federico, M., Rashid, I., Cirilli, C., Fusco, M., Traina, A., De Lisi, V., Bozzani, F., Magnani, C., Pastore, G., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Mangone, L., Falcini, F., Foca, F., Giorgetti, S., Senatore, G., Iannelli, A., Budroni, M., Zanetti, R., Patriarca, S., Rosso, S., Piffer, S., Paci, E., Crocetti, E., La Rosa, F., Stracci, F., Cassetti, T., Zambon, P., Guzzinati, S., Caldora, M., Capocaccia, R., Carrani, E., De Angelis, R., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Dalmas, M., England, K., Micallef, R., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Go´ z´dz´, S., Siudowska, U., Me?z? yk, R., Bielska-Lasota, M., Sklodowska, M., Zwierko, M., Miranda, A., Diba, C. S., Plesko, I., Primic-Z?akelj, M., Mateos, A., Izarzugaza, I., Torrella-Ramos, A., Zurriaga, O., Marcos-Gragera, R., Vilardell, M. L., Izquierdo, A., Martinez-Garcia, C., Saâ´nchez, M. J., Navarro, C., Chirlaque, M. D., Peris-Bonet, R., Ardanaz, E., Moreno, C., Galceran, J., Klint, A., Talbaâck, M., Khan, S., Jundt, G., Usel, M., Frick, H., Ess, S. M., Bordoni, A., Konzelmann, I., Dehler, S., Lutz, J. M., Pury, P., Siesling, S., Visser, O., Otter, R., Coebergh, J. W. W., Janssen-Heijnen, M. L., Louis van der Heijden, Null, Greenberg, D. C., Coleman, M. P., Woods, L., Moran, T., Forman, D., Cooper, N., Roche, M., Verne, J., Mã¸ller, H., Meechan, D., Poole, J., Lawrence, G., Stiller, C., Black, R. J., Brewster, D. H., Steward, J. A., Bouchardy Magnin, Christine, and Usel, Massimo

Subjects
Stage, Adult, Male, Cancer Research, Survival, Adolescent, Esophageal Neoplasms, Epidemiology, Socio-culturale, Subtype, Disease, Europe/epidemiology, Young Adult, Cancer, Europe, Oesophagus, Trends, Aged, Aged, 80 and over, Female, Humans, Middle Aged, Neoplasm Staging, Prognosis, Registries, Survival Rate, Oncology, medicine, 80 and over, Young adult, Stage (cooking), cancer survival, Survival rate, ddc:613, Relative survival, business.industry, Oesophageal cancer, Cancer survival, medicine.disease, Esophageal Neoplasms/mortality/pathology, business, Demography, Cohort study
Abstract

Oesophageal cancer survival is poor with variation across Europe. No pan-European studies of survival differences by oesophageal cancer subtype exist. This study investigates rates and trends in oesophageal cancer survival across Europe. Data for primary malignant oesophageal cancer diagnosed in 1995-1999 and followed up to the end of 2003 was obtained from 66 cancer registries in 24 European countries. Relative survival was calculated using the Hakulinen approach. Staging data were available from 19 registries. Survival by region, gender, age, morphology and stage was investigated. Cohort analysis and the period approach were applied to investigate survival trends from 1988 to 2002 for 31 registries in 17 countries. In total 51,499 cases of oesophageal cancer diagnosed 1995-1999 were analysed. Overall, European 1- and 5-year survival rates were 33.4% (95% CI 32.9-33.9%) and 9.8% (95% CI 9.4-10.1%), respectively. Males, older patients and patients with late stage disease had poorer 1- and 5-year relative survival. Patients with squamous cell carcinoma had poorer 1-year relative survival. Regional variation in survival was observed with Central Europe above and Eastern Europe below the European pool. Survival for distant stage disease was similar across Europe while survival rates for localised disease were below the European pool in Eastern and Southern Europe. Improvement in European 1-year relative survival was reported (p=0.016). Oesophageal cancer survival was poor across Europe. Persistent regional variations in 1-year survival point to a need for a high resolution study of diagnostic and treatment practices of oesophageal cancer.

Published
2012

11. Rare cancers are not so rare: the rare cancer burden in Europe

Author

Gatta, Gemma, Van Der Zwan, Jan Maarten, Casali, Paolo G., Siesling, Sabine, Dei Tos, Angelo Paolo, Kunkler, Ian, Otter, Renã©e, Licitra, Lisa, Mallone, Sandra, Tavilla, Andrea, Trama, Annalisa, Capocaccia, Riccardo, Hackl, M., Van Eycken, E., Schrijvers, D., Sundseth, H., Geissler, Jan, Marreaud, S., Audisio, R., Mã¤gi, M., Hedelin, G., Velten, M., Launoy, G., Guizard, A. V., Bouvier, A. M., Maynadiã©, M., Mercier, M., Buemi, A., Tretarre, B., Colonna, M., Moliniã©, F., Lacour, B., Schvartz, C., Ganry, O., Grosclaude, P., Benhamou, E., Grossgoupil, M., Coquard, I. R., Droz, J. P., Baconnier, S., Holleczek, B., Wartenberg, M., Hehlmann, R., Tryggvadottir, L., Deady, S., Bellã¹, F., Ferretti, S., Serraino, D., Vercelli, M., Vitarelli, S., Cirilli, C., Fusco, M., Traina, A., Michiara, M., Giacomin, A., Pastore, G., Tumino, R., Mangone, L., Falcini, F., Senatore, G., Budroni, M., Piffer, S., Crocetti, E., La Rosa, F., Contiero, P., Zambon, P., Berrino, F., Casali, P. G., Gatta, G., Gronchi, A., Licitra, L., Sowe, S., Trama, A., Capocaccia, R., De Angelis, R., Mallone, S., Tavilla, A., Dei Tos, A. P., Brandes, A. A., England, K., Langmark, F., Rachtan, J., Mezyk, R., Zwierko, M., Bielska-lasota, M., Slowinski, J., Miranda, A., Safaei Diba, Ch, Primic-zakelj, M., Mateos, A., Izarzugaza, I., Marcos-gragera, R., Sã¡nchez, M. J., Navarro, C., Ardanaz, Eva, Galceran, J., Virizuela-echaburu, J. A., Martinez-garcia, C., Melchor, J. M., Cervantes, A., Adolfsson, Jan, Lambe, M., Mã¶ller, T. R., Ringborg, Ulrik, Jundt, G., Usel, M., Frick, H., Ess, S. M., Bordoni, A., Konzelmann, I., Dehler, S., Lutz, J. M., Visser, O., Otter, R., Siesling, S., Van Der Zwan, J. M., Coebergh, J. W. W., Schouten, H., Greenberg, D. C., Wilkinson, J., Roche, M., Verne, J., Meechan, D., Lawrence, G., Coleman, M. P., Mackay, J., Gavin, A., Brewster, D. H., Kunkler, I., Steward, J., Evaluative Epidemiology Unit, Fondazione IRCCS, Comprehensive Cancer Centre North East, University of Twente [Netherlands], Cancer Research UK Edinburgh Centre [Edinburgh, UK], University of Edinburgh-MRC Institute of Genetics and Molecular Medicine [Edinburgh] (IGMM), University of Edinburgh-Medical Research Council-Medical Research Council, Integraal Kankercentrum Noord, National Centre for Epidemiology, Surveillance and Health Promotion, Istituto Superiore di Sanita [Rome], Fondazione IRCCS Istituto Nazionale dei Tumori, Faculty of Behavioural, Management and Social Sciences, and Usel, Massimo

Subjects
Male, Pediatrics, Cancer Research, Survival, Rare cancers, Europe, MESH: Registries, 0302 clinical medicine, MESH: Aged, 80 and over, Rare Diseases/epidemiology, Neoplasms, MESH: Child, Prevalence, Cancer registries, MESH: Neoplasms, Registries, MESH: Incidence, Child, media_common, Aged, 80 and over, MESH: Aged, 0303 health sciences, education.field_of_study, MESH: Middle Aged, Relative survival, Incidence (epidemiology), Incidence, MESH: Infant, Newborn, IR-78337, Middle Aged, MESH: Infant, 3. Good health, Oncology, MESH: Young Adult, 030220 oncology & carcinogenesis, Child, Preschool, MESH: Survival Analysis, Female, Adult, MESH: Rare Diseases, medicine.medical_specialty, Adolescent, Population, [SDV.CAN]Life Sciences [q-bio]/Cancer, Rare cancers, Cancer registries, Incidence, Prevalence, Survival, Europe/epidemiology, NO, 03 medical and health sciences, Young Adult, Rare Diseases, medicine, media_common.cataloged_instance, Humans, European union, education, Survival analysis, MESH: Prevalence, 030304 developmental biology, ddc:613, Aged, MESH: Adolescent, MESH: Humans, business.industry, Public health, MESH: Child, Preschool, Infant, Newborn, Cancer, Infant, MESH: Adult, medicine.disease, Survival Analysis, MESH: Male, Cancer registry, MESH: Europe, business, Neoplasms/epidemiology, MESH: Female
Abstract

International audience; PURPOSE: Epidemiologic information on rare cancers is scarce. The project Surveillance of Rare Cancers in Europe (RARECARE) provides estimates of the incidence, prevalence and survival of rare cancers in Europe based on a new and comprehensive list of these diseases. MATERIALS AND METHODS: RARECARE analysed population-based cancer registry (CR) data on European patients diagnosed from 1988 to 2002, with vital status information available up to 31st December 2003 (latest date for which most CRs had verified data). The mean population covered was about 162,000,000. Cancer incidence and survival rates for 1995-2002 and prevalence at 1st January 2003 were estimated. RESULTS: Based on the RARECARE definition (incidence

Published
2011

12. Survival of European patients with central nervous system tumors

Author

Sant, Milena, Minicozzi, Pamela, Lagorio, Susanna, Børge Johannesen, Tom, Marcos-Gragera, Rafael, Francisci, Silvia, Oberaigner, W., Hackl, M., Van Eycken, E., Verstreken, Martine, Holub, J., Jurickova, L., Storm, H. H., Engholm, G., Hakulinen, T., Belot, A., Hã©delin, G., Velten, M., Guizard, A. V., Danzon, A., Buemi, A., Tretarre, B., Colonna, M., Bara, S., Ganry, O., Grosclaude, P., Ziegler, H., Tryggvadottir, L., Comber, H., Berrino, F., Allemani, C., Baili, P., Ciampichini, R., Ciccolallo, L., Gatta, G., Margutti, C., Micheli, A., Minicozzi, P., Sant, M., Sowe, S., Tereanu, C., Zigon, G., Tagliabue, G., Contiero, P., Bellã¹, F., Giacomin, A., Ferretti, S., Serraino, D., Dal Maso, L., De Dottori, M., De Paoli, A., Zanier, L., Vercelli, M., Orengo, M. A., Casella, C., Quaglia, A., Pannelli, F., Federico, M., Rashid, I., Cirilli, C., Fusco, M., De Lisi, V., Bozzani, F., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Mangone, L., Falcini, F., Foca, F., Giorgetti, S., Senatore, G., Iannelli, A., Budroni, M., Zanetti, R., Patriarca, S., Rosso, S., Piffer, S., Franchini, S., Paci, E., Crocetti, E., La Rosa, F., Stracci, F., Cassetti, T., Zambon, P., Guzzinati, S., Caldora, M., Capocaccia, R., Carrani, E., De Angelis, R., Francisci, S., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Dalmas, M., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Gã³åºdåº, S., Siudowska, U., Mezyk, R., Bielska-Lasota, M., Zwierko, M., Miranda, A., Safaei Diba, Chakameh, Primic-Źakelj, M., Izarzugaza, I., Marcos-Gragera, R., Vilardell, M. L., Izquierdo, A., Navarro, C., Chirlaque, M. D., Ardanaz, E., Moreno, C., Galceran, J., Klint, Ã. …., Talbã¤ck, M., Jundt, G., Usel, M., Ess, S. M., Bordoni, A., Luthi, J. C., Konzelmann, I., Lutz, J. M., Pury, P., Visser, O., Otter, R., Siesling, S., van der Zwan, J. M., Schaapveld, M., Coebergh, J. W. W., Janssen-Heijnen, M. L., van der Heijden, Louis, Greenberg, D. C., Coleman, M. P., Woods, Laura, Moran, T., Forman, D., Cooper, N., Roche, M., Verne, J., Mã¸ller, H., Meechan, D., Poole, J., Lawrence, G., Gavin, A., Black, R. J., Brewster, D. H., Steward, J. A., and Usel, Massimo

Subjects
Oncology, Ependymoma, Adult, Male, medicine.medical_specialty, Pathology, Cancer Research, Adolescent, Central Nervous System Neoplasms/mortality, Population, survival, NO, Benign tumor, Central Nervous System Neoplasms, Young Adult, Sex Factors, Internal medicine, morphology, medicine, 80 and over, Humans, Registries, Young adult, central nervous system tumors, Europe, Age Factors, Aged, Aged, 80 and over, Female, Middle Aged, Survival Rate, education, Survival rate, ddc:613, Medulloblastoma, education.field_of_study, Relative survival, business.industry, Cancer survival, Cancer, central nervous system tumors, survival, morphology, Europe, medicine.disease, business
Abstract

We present estimates of population-based 5-year relative survival for adult Europeans diagnosed with central nervous system tumors, by morphology (14 categories based on cell lineage and malignancy grade), sex, age at diagnosis and region (UK and Ireland, Northern, Central, Eastern and Southern Europe) for the most recent period with available data (2000-2002). Sources were 39 EUROCARE cancer registries with continuous data from 1996 to 2002. Survival time trends (1988 to 2002) were estimated from 24 cancer registries with continuous data from 1988. Overall 5-year relative survival was 85.0% for benign, 19.9% for malignant tumors. Benign tumor survival ranged from 90.6% (Northern Europe) to 77.4% (UK and Ireland); for malignant tumors the range was 25.1% (Northern Europe) to 15.6% (UK and Ireland). Survival decreased with age at diagnosis and was slightly better for women (malignant tumors only). For glial tumors, survival varied from 83.5% (ependymoma and choroid plexus) to 2.7% (glioblastoma); and for non-glioma tumors from 96.5% (neurinoma) to 44.9% (primitive neuroectoderm tumor/medulloblastoma). Survival differences between regions narrowed after adjustment for morphology and age, and were mainly attributable to differences in morphology mix; however UK and Ireland and Eastern Europe patients still had 40% and 30% higher excess risk of death, respectively, than Northern Europe patients (reference). Survival for benign tumors increased from 69.3% (1988-1990) to 77.1% (2000-2002); but survival for malignant tumors did not improve indicating no useful advances in treatment over the 14-year study period, notwithstanding major improvement in the diagnosis and treatment of other solid cancers.

Published
2011

13. Survival trends in European cancer patients diagnosed from 1988 to 1999

Author

Verdecchia, Arduino, Guzzinati, Stefano, Francisci, Silvia, De Angelis, Roberta, Bray, Freddie, Allemani, Claudia, Tavilla, Andrea, Santaquilani, Mariano, Sant, Milena, Gavin, A., Black, R. J., Brewster, D. H., Steward, J. A., Oberaigner, W., Hackl, M., Van Eycken, E., Verstreken, Martine, Holub, J., Jurickova, L., Storm, H. H., Engholm, G., Hakulinen, T., Belot, A., Hã©delin, G., Velten, M., Tron, I., Le Gall, E., Launoy, G., Guizard, A. V., Faivre, J., Bouvier, A. M., Carli, P. M., Maynadiã©, M., Danzon, A., Buemi, A., Tretarre, B., Lacour, B., Desandes, E., Colonna, M., Moliniã©, F., Bara, S., Schvartz, C., Ganry, O., Grosclaude, P., Brenner, H., Kaatsch, P., Ziegler, H., Tryggvadottir, L., Comber, H., Berrino, F., Allemani, C., Baili, P., Ciampichini, R., Ciccolallo, L., Gatta, G., Micheli, A., Sant, M., Sowe, S., Zigon, G., Tagliabue, G., Contiero, P., Bellã¹, F., Giacomin, A., Ferretti, S., Dal Maso, D. Serraino L., De Dottori, M., De Paoli, A., Zanier, L., Vercelli, M., Orengo, M. A., Casella, C., Quaglia, A., Pannelli, F., Federico, M., Rashid, I., Cirilli, C., Fusco, M., Traina, A., De Lisi, V., Bozzani, F., Magnani, C., Pastore, G., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Mangone, L., Falcini, F., Foca, F., Giorgetti, S., Senatore, G., Iannelli, A., Budroni, M., Zanetti, R., Patriarca, S., Rosso, S., Piffer, S., Franchini, S., Paci, E., Crocetti, E., La Rosa, F., Stracci, F., Cassetti, T., Zambon, P., Guzzinati, S., Caldora, M., Capocaccia, R., Carrani, E., Francisci, S., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Dalmas, M., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Gã³åºdåº, S., Siudowska, U., Mè©zyk, R., Bielska-Lasota, M., Zwierko, M., Pinheiro, P. S., Primic-Žakelj, M. P. -. Z., Mateos, A., Izarzugaza, I., Torrella-Ramos, A., Zurriaga, Oscar, Marcos-Gragera, R., Vilardell, M. L., Izquierdo, A., Martinez-Garcia, C., Sã¡nchez, M. J., Navarro, C., Chirlaque, M. D., Peris-Bonet, R., Ardanaz, E., Moreno, C., Galceran, J., Klint, Ã. …., Talbã¤ck, M., Jundt, G., Usel, M., Frick, H., Ess, S. M., Bordoni, A., Luthi, J. C., Konzelmann, I., Probst, N., Lutz, J. M., Pury, P., Visser, O., Otter, R., Schaapveld, M., Coebergh, J. W. W., Janssen-Heijnen, M. L., Van Der Heijden, Louis, Greenberg, D. C., Coleman, M. P., Woods, Laura, Moran, T., Forman, D., Cooper, N., Roche, M., Verne, J., Mã¸ller, H., Meechan, D., Poole, J., Lawrence, G., Stiller, C., Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, National Centre for Epidemiology, Surveillance and Health Promotion, Istituto Superiore di Sanita [Rome], Department of Preventive and Predictive Medicine, Unit of Etiological Epidemiology and Prevention, Istituto Nazionale per lo Studio e la Cura dei Tumori, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), and Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC )

Subjects
Male, Cancer Research, Survival, MESH : Mortality, MESH : Age Distribution, MESH : Aged, Colonoscopy, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, MESH: Aged, 80 and over, Prostate, Residence Characteristics, Neoplasms, 80 and over, MESH : Female, MESH: Neoplasms, 030212 general & internal medicine, MESH: Residence Characteristics, Young adult, cancer survival, MESH : Sex Distribution, Aged, 80 and over, MESH: Aged, MESH: Middle Aged, medicine.diagnostic_test, Relative survival, Europe, Population registries, Time trends, Adolescent, Adult, Age Distribution, Aged, Female, Humans, Middle Aged, Mortality, Sex Distribution, Survival Analysis, Young Adult, Oncology, MESH: Sex Distribution, MESH : Adult, 3. Good health, medicine.anatomical_structure, MESH: Young Adult, 030220 oncology & carcinogenesis, MESH: Survival Analysis, MESH : Residence Characteristics, medicine.medical_specialty, MESH : Male, MESH : Europe, MESH : Young Adult, Socio-culturale, Rectum, [SDV.CAN]Life Sciences [q-bio]/Cancer, 03 medical and health sciences, Internal medicine, MESH : Adolescent, medicine, MESH : Middle Aged, MESH : Aged, 80 and over, Cervix, MESH: Age Distribution, Survival analysis, MESH: Adolescent, MESH: Humans, MESH: Mortality, business.industry, MESH : Humans, Cancer, MESH: Adult, medicine.disease, MESH : Neoplasms, MESH: Male, Surgery, MESH: Europe, MESH : Survival Analysis, business, MESH: Female
Abstract

International audience; We analysed data from 49 cancer registries in 18 European countries over the period 1988-1999 to delineate time trends in cancer survival. Survival increased in Europe over the study period for all cancer sites that were considered. There were major survival increases in 5 year age-adjusted relative survival for prostate (from 58% to 79%), colon and rectum (from 48% to 54% men and women), and breast (from 74% to 83%). Improvements were also significant for stomach (from 22% to 24%), male larynx (from 62% to 64%), skin melanoma (from 78% to 83%), Hodgkin disease (from 77% to 83%), non-Hodgkin lymphoma (from 49% to 56%), leukaemias (from 37% to 42%), and for all cancers combined (from 34% to 39% in men, and from 52% to 59% in women). Survival did not change significantly for female larynx, lung, cervix or ovary. The largest increases in survival typically occurred in countries with the lowest survival, and contributed to the overall reduction of survival disparities across Europe over the study period. Differences in the extent of PSA testing and mammographic screening, and increasing use of colonoscopy and faecal blood testing together with improving cancer care are probably the major underlying reasons for the improvements in survival for cancers of prostate, breast, colon and rectum. The marked survival improvements in countries with poor survival may indicate that these countries have made efforts to adopt the new diagnostic procedures and the standardised therapeutic protocols in use in more affluent countries.

Published
2009

14. The EUROCARE-4 database on cancer survival in Europe: data standardisation, quality control and methods of statistical analysis

Author

De Angelis, Roberta, Francisci, Silvia, Baili, Paolo, Marchesi, Francesca, Roazzi, Paolo, Belot, Aurã©lien, Crocetti, Emanuele, Pury, Pierre, Knijn, Arnold, Coleman, Michel, Capocaccia, Riccardo, Holub, J., Jurickova, L., Storm, H. H., Engholm, G., Hakulinen, T., Belot, A., Hã©delin, G., Velten, M., Tron, I., Le Gall, E., Launoy, G., Guizard, A. V., Faivre, J., Bouvier, A. M., Carli, P. M., Maynadiã©, M., Danzon, A., Buemi, A., Tretarre, B., Lacour, B., Desandes, E., Colonna, M., Moliniã©, F., Bara, S., Schvartz, C., Ganry, O., Grosclaude, P., Brenner, H., Kaatsch, P., Ziegler, H., Tryggvadottir, L., Comber, H., Berrino, F., Allemani, C., Baili, P., Ciampichini, R., Ciccolallo, L., Gatta, G., Micheli, A., Sant, M., Sowe, S., Zigon, G., Tagliabue, G., Contiero, P., Bellã¹, F., Giacomin, A., Ferretti, S., Dal Maso, D. Serraino L., De Dottori, M., De Paoli, A., Zanier, L., Vercelli, M., Orengo, M. A., Casella, C., Quaglia, A., Pannelli, F., Federico, M., Rashid, I., Cirilli, C., Fusco, M., Traina, A., De Lisi, V., Bozzani, F., Magnani, C., Pastore, G., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Mangone, L., Falcini, F., Foca, F., Giorgetti, S., Senatore, G., Iannelli, A., Budroni, M., Zanetti, R., Patriarca, S., Rosso, S., Piffer, S., Franchini, S., Paci, E., Crocetti, E., La Rosa, F., Stracci, F., Cassetti, T., Zambon, P., Guzzinati, S., Caldora, M., Capocaccia, R., Carrani, E., Francisci, S., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Dalmas, M., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Gã³åºdåº, S., Siudowska, U., Mè©zyk, R., Bielska-Lasota, M., Zwierko, M., Pinheiro, P. S., Primic-Žakelj, M. P. -. Z., Mateos, A., Izarzugaza, I., Torrella-Ramos, A., Zurriaga, Oscar, Marcos-Gragera, R., Vilardell, M. L., Izquierdo, A., Martinez-Garcia, C., Sã¡nchez, M. J., Navarro, C., Chirlaque, M. D., Peris-Bonet, R., Ardanaz, E., Moreno, C., Galceran, J., Klint, Ã. …., Talbã¤ck, M., Jundt, G., Usel, M., Frick, H., Ess, S. M., Bordoni, A., Luthi, J. C., Konzelmann, I., Probst, N., Lutz, J. M., Pury, P., Visser, O., Otter, R., Schaapveld, M., Coebergh, J. W. W., Janssen-Heijnen, M. L., Van Der Heijden, Louis, Greenberg, D. C., Coleman, M. P., Woods, Laura, Moran, T., Forman, D., Cooper, N., Roche, M., Verne, J., Mã¸ller, H., Meechan, D., Poole, J., Lawrence, G., Stiller, C., Gavin, A., Black, R. J., Brewster, D. H., Steward, J. A., Oberaigner, W., Hackl, M., Van Eycken, E., Verstreken, Martine, Service de Biostatistique, Hospices Civils de Lyon ( HCL ), Laboratoire de Biométrie et Biologie Evolutive ( LBBE ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique ( Inria ) -Centre National de la Recherche Scientifique ( CNRS ), Département des maladies chroniques et traumatismes, Institut de Veille Sanitaire (INVS), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Hospices Civils de Lyon (HCL), Biostatistiques santé, Département biostatistiques et modélisation pour la santé et l'environnement [LBBE], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (UR 3181) (CEF2P / CARCINO), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)

Subjects
Cancer Research, MESH: Quality Control, computer.software_genre, MESH: Epidemiologic Methods, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, Neoplasms, Medicine, MESH: Neoplasms, 030212 general & internal medicine, cancer survival, education.field_of_study, Database, Relative survival, Incidence (epidemiology), Europe, Population registries, Survival analysis, Vital statistics, Databases as Topic, Epidemiologic Methods, Humans, Quality Control, Oncology, MESH : Quality Control, 3. Good health, 030220 oncology & carcinogenesis, Population, MESH : Europe, MEDLINE, Socio-culturale, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH : Epidemiologic Methods, 03 medical and health sciences, education, MESH: Humans, business.industry, MESH : Humans, Cancer, medicine.disease, MESH : Neoplasms, Data quality, MESH: Europe, MESH : Databases as Topic, business, computer, MESH: Databases as Topic, International Classification of Diseases for Oncology
Abstract

International audience; This paper describes the collection, standardisation and checking of cancer survival data included in the EUROCARE-4 database. Methods for estimating relative survival are also described. Incidence and vital status data on newly diagnosed European cancer cases were received from 93 cancer registries in 23 countries, covering 151,400,000 people (35% of the participating country population). The third revision of the International Classification of Diseases for Oncology was used to specify tumour topography and morphology. Records were extensively checked for consistency and compatibility using multiple routines; flagged records were sent back for correction. An algorithm assigned standardised sequence numbers to multiple cancers. Only first malignant cancers were used to estimate relative survival from registry, year, sex and age-specific life tables. Age-adjusted and Europe-wide survival were also estimated. The database contains 13,814,573 cases diagnosed in 1978-2002; 92% malignant. A negligible proportion of records was excluded for major errors. Of 5,753,934 malignant adult cases diagnosed in 1995-2002, 5.3% were second or later cancers, 2.7% were known from death certificates only and 0.4% were discovered at autopsy. The remaining 5,278,670 cases entered the survival analyses, 90% of these had microscopic confirmation and 1.3% were censored alive after less than five years' follow-up. These indicators suggest satisfactory data quality that has improved since EUROCARE-3.

Published
2009

15. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary

Author

Sant, Milena, Allemani, Claudia, Santaquilani, Mariano, Knijn, Arnold, Marchesi, Francesca, Capocaccia, Riccardo, Stiller, C., Gavin, A., Black, R. J., Brewster, D. H., Steward, J. A., Oberaigner, W., Hackl, M., Van Eycken, E., Verstreken, Martine, Holub, J., Jurickova, L., Storm, H. H., Engholm, G., Hakulinen, T., Belot, A., Hã©delin, G., Velten, M., Tron, I., Le Gall, E., Launoy, G., Guizard, A. V., Faivre, J., Bouvier, A. M., Carli, P. M., Maynadiã©, M., Danzon, A., Buemi, A., Tretarre, B., Lacour, B., Desandes, E., Colonna, M., Moliniã©, F., Bara, S., Schvartz, C., Ganry, O., Grosclaude, P., Brenner, H., Kaatsch, P., Ziegler, H., Tryggvadottir, L., Comber, H., Berrino, F., Allemani, C., Baili, P., Ciampichini, R., Ciccolallo, L., Gatta, G., Micheli, A., Sant, M., Sowe, S., Zigon, G., Tagliabue, G., Contiero, P., Bellã¹, F., Giacomin, A., Ferretti, S., Dal Maso, D. Serraino L., De Dottori, M., De Paoli, A., Zanier, L., Vercelli, M., Orengo, M. A., Casella, C., Quaglia, A., Pannelli, F., Federico, M., Rashid, I., Cirilli, C., Fusco, M., Traina, A., De Lisi, V., Bozzani, F., Magnani, C., Pastore, G., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Mangone, L., Falcini, F., Foca, F., Giorgetti, S., Senatore, G., Iannelli, A., Budroni, M., Zanetti, R., Patriarca, S., Rosso, S., Piffer, S., Franchini, S., Paci, E., Crocetti, E., La Rosa, F., Stracci, F., Cassetti, T., Zambon, P., Guzzinati, S., Caldora, M., Capocaccia, R., Carrani, E., De Angelis, R., Francisci, S., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Dalmas, M., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Gã³åºdåº, S., Siudowska, U., Mè©zyk, R., Bielska-Lasota, M., Zwierko, M., Pinheiro, P. S., Primic-Žakelj, M. P. -. Z., Mateos, A., Izarzugaza, I., Torrella-Ramos, A., Zurriaga, Oscar, Marcos-Gragera, R., Vilardell, M. L., Izquierdo, A., Martinez-Garcia, C., Sã¡nchez, M. J., Navarro, C., Chirlaque, M. D., Peris-Bonet, R., Ardanaz, E., Moreno, C., Galceran, J., Klint, Ã. …., Talbã¤ck, M., Jundt, G., Usel, M., Frick, H., Ess, S. M., Bordoni, A., Luthi, J. C., Konzelmann, I., Probst, N., Lutz, J. M., Pury, P., Visser, O., Otter, R., Schaapveld, M., Coebergh, J. W. W., Janssen-Heijnen, M. L., Van Der Heijden, Louis, Greenberg, D. C., Coleman, M. P., Woods, Laura, Moran, T., Forman, D., Cooper, N., Roche, M., Verne, J., Mã¸ller, H., Meechan, D., Poole, J., Lawrence, G., Department of Preventive and Predictive Medicine, Unit of Etiological Epidemiology and Prevention, Istituto Nazionale per lo Studio e la Cura dei Tumori, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), and Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC )

Subjects
Male, Cancer Research, MESH : Age Distribution, MESH : Aged, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, Neoplasms, Epidemiology, Medicine, MESH : Female, MESH: Neoplasms, 030212 general & internal medicine, MESH : Sex Distribution, MESH: Aged, MESH: Middle Aged, Relative survival, MESH: Sex Distribution, Population-based cancer registries, Middle Aged, MESH : Adult, Cancer survival, EUROCARE, Adolescent, Adult, Age Distribution, Aged, Europe, Female, Humans, Sex Distribution, Survival Analysis, Oncology, 3. Good health, 030220 oncology & carcinogenesis, MESH: Survival Analysis, Skin melanoma, Stage at diagnosis, medicine.medical_specialty, MESH : Male, MESH : Europe, Socio-culturale, [SDV.CAN]Life Sciences [q-bio]/Cancer, Age and sex, 03 medical and health sciences, MESH : Adolescent, MESH : Middle Aged, MESH: Age Distribution, Survival analysis, MESH: Adolescent, MESH: Humans, business.industry, Advanced stage, MESH : Humans, Cancer, MESH: Adult, medicine.disease, MESH : Neoplasms, MESH: Male, MESH: Europe, MESH : Survival Analysis, business, MESH: Female, Demography
Abstract

International audience; EUROCARE-4 analysed about three million adult cancer cases from 82 cancer registries in 23 European countries, diagnosed in 1995-1999 and followed to December 2003. For each cancer site, the mean European area-weighted observed and relative survival at 1-, 3-, and 5-years by age and sex are presented. Country-specific 1- and 5-year relative survival is also shown, together with 5-year relative survival conditional to surviving 1-year. Within-country variation in survival is analysed for selected cancers. Survival for most solid cancers, whose prognosis depends largely on stage at diagnosis (breast, colorectum, stomach, skin melanoma), was highest in Finland, Sweden, Norway and Iceland, lower in the UK and Denmark, and lowest in the Czech Republic, Poland and Slovenia. France, Switzerland and Italy generally had high survival, slightly below that in the northern countries. There were between-region differences in the survival for haematologic malignancies, possibly due to differences in the availability of effective treatments. Survival of elderly patients was low probably due to advanced stage at diagnosis, comorbidities, difficult access or lack of availability of appropriate care. For all cancers, 5-year survival conditional to surviving 1-year was higher and varied less with region, than the overall relative survival.

Published
2009

16. The cure of cancer: a european perspective

Author

Francisci, Silvia, Capocaccia, Riccardo, Grande, Enrico, Santaquilani, Mariano, Simonetti, Arianna, Allemani, Claudia, Gatta, Gemma, Sant, Milena, Zigon, Giulia, Bray, Freddie, Janssen-Heijnen, Maryska, Steward, J. A., Oberaigner, W., Hackl, M., Van Eycken, E., Verstreken, Martine, Holub, J., Jurickova, L., Storm, H. H., Engholm, G., Hakulinen, T., Belot, A., Hã©delin, G., Velten, M., Tron, I., Le Gall, E., Launoy, G., Guizard, A. V., Faivre, J., Bouvier, A. M., Carli, P. M., Maynadiã©, M., Danzon, A., Buemi, A., Tretarre, B., Lacour, B., Desandes, E., Colonna, M., Moliniã©, F., Bara, S., Schvartz, C., Ganry, O., Grosclaude, P., Brenner, H., Kaatsch, P., Ziegler, H., Tryggvadottir, L., Comber, H., Berrino, F., Allemani, C., Baili, P., Ciampichini, R., Ciccolallo, L., Gatta, G., Micheli, A., Sant, M., Sowe, S., Zigon, G., Tagliabue, G., Contiero, P., Bellã¹, F., Giacomin, A., Ferretti, S., Dal Maso, D. Serraino L., De Dottori, M., De Paoli, A., Zanier, L., Vercelli, M., Orengo, M. A., Casella, C., Quaglia, A., Pannelli, F., Federico, M., Rashid, I., Cirilli, C., Fusco, M., Traina, A., De Lisi, V., Bozzani, F., Magnani, C., Pastore, G., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Mangone, L., Falcini, F., Foca, F., Giorgetti, S., Senatore, G., Iannelli, A., Budroni, M., Zanetti, R., Patriarca, S., Rosso, S., Piffer, S., Franchini, S., Paci, E., Crocetti, E., La Rosa, F., Stracci, F., Cassetti, T., Zambon, P., Guzzinati, S., Caldora, M., Capocaccia, R., Carrani, E., De Angelis, R., Francisci, S., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Dalmas, M., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Gã³åºdåº, S., Siudowska, U., Mè©zyk, R., Bielska-Lasota, M., Zwierko, M., Pinheiro, P. S., Primic-Žakelj, M. P. -. Z., Mateos, A., Izarzugaza, I., Torrella-Ramos, A., Zurriaga, Oscar, Marcos-Gragera, R., Vilardell, M. L., Izquierdo, A., Martinez-Garcia, C., Sã¡nchez, M. J., Navarro, C., Chirlaque, M. D., Peris-Bonet, R., Ardanaz, E., Moreno, C., Galceran, J., Klint, Ã. …., Talbã¤ck, M., Jundt, G., Usel, M., Frick, H., Ess, S. M., Bordoni, A., Luthi, J. C., Konzelmann, I., Probst, N., Lutz, J. M., Pury, P., Visser, O., Otter, R., Schaapveld, M., Coebergh, J. W. W., Janssen-Heijnen, M. L., Van Der Heijden, Louis, Greenberg, D. C., Coleman, M. P., Woods, Laura, Moran, T., Forman, D., Cooper, N., Roche, M., Verne, J., Mã¸ller, H., Meechan, D., Poole, J., Lawrence, G., Stiller, C., Gavin, A., Black, R. J., Brewster, D. H., National Centre for Epidemiology, Surveillance and Health Promotion, Istituto Superiore di Sanita [Rome], Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Evaluative Epidemiology Unit, Fondazione IRCCS, Department of Preventive and Predictive Medicine, Unit of Etiological Epidemiology and Prevention, Istituto Nazionale per lo Studio e la Cura dei Tumori, Eindhoven Cancer Registry, Comprehensive Cancer Centre South, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), and Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC )

Subjects
Male, Cancer Research, Colorectal cancer, MESH : Age Distribution, MESH : Aged, Gastroenterology, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, Prostate cancer, 0302 clinical medicine, Breast cancer, MESH: Aged, 80 and over, Colon and rectum cancer, Cure, Lung cancer, Relative survival, Statistical models, Stomach cancer, Oncology, Neoplasms, MESH : Female, MESH: Neoplasms, 030212 general & internal medicine, cancer survival, Aged, 80 and over, MESH: Aged, MESH : Prognosis, MESH: Middle Aged, Middle Aged, MESH : Adult, Prognosis, 3. Good health, Europe, MESH: Young Adult, 030220 oncology & carcinogenesis, MESH: Survival Analysis, Female, Adult, medicine.medical_specialty, Adolescent, MESH : Male, MESH : Europe, MESH : Young Adult, Socio-culturale, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH: Prognosis, 03 medical and health sciences, Young Adult, Age Distribution, Internal medicine, MESH : Adolescent, medicine, Humans, MESH : Middle Aged, MESH : Aged, 80 and over, MESH: Age Distribution, Aged, MESH: Adolescent, MESH: Humans, business.industry, MESH : Humans, Cancer, MESH: Adult, medicine.disease, Survival Analysis, MESH : Neoplasms, MESH: Male, Cancer registry, MESH: Europe, MESH : Survival Analysis, business, MESH: Female
Abstract

International audience; Cancer survival analyses based on cancer registry data do not provide direct information on the main aim of cancer treatment, the cure of the patient. In fact, classic survival indicators do not distinguish between patients who are cured, and patients who will die of their disease and in whom prolongation of survival is the main objective of treatment. In this study, we applied parametric cure models to the cancer incidence and follow-up data provided by 49 EUROCARE-4 (European Cancer Registry-based study, fourth edition) cancer registries, with the aims of providing additional insights into the survival of European cancer patients diagnosed from 1988 to 1999, and of investigating between-population differences. Between-country estimates the proportion of cured patients varied from about 4-13% for lung cancer, from 9% to 30% for stomach cancer, from 25% to 49% for colon and rectum cancer, and from 55% to 73% for breast cancer. For all cancers combined, estimates varied between 21% and 47% in men, and 38% and 59% in women and were influenced by the distribution of cases by cancer site. Countries with high proportions of cured and long fatal case survival times for all cancers combined were characterised by generally favourable case mix. For the European pool of cases both the proportion of cured and the survival time of fatal cases were associated with age, and increased from the early to the latest diagnosis period. The increases over time in the proportions of Europeans estimated cured of lung, stomach and colon and rectum cancers are noteworthy and suggest genuine progress in cancer control. The proportion of cured of all cancers combined is a useful general indicator of cancer control as it reflects progress in diagnosis and treatment, as well as success in the prevention of rapidly fatal cancers.

Published
2009

17. Long-term survival expectations of cancer patients in Europe in 2000-2002

Author

Brenner, Hermann, Francisci, Silvia, De Angelis, Roberta, Marcos-Gragera, Rafael, Verdecchia, Arduino, Gatta, Gemma, Allemani, Claudia, Ciccolallo, Laura, Coleman, Michel, Sant, Milena, Oberaigner, W., Hackl, M., Van Eycken, E., Verstreken, Martine, Holub, J., Jurickova, L., Storm, H. H., Engholm, G., Hakulinen, T., Belot, A., Hã©delin, G., Velten, M., Tron, I., Le Gall, E., Launoy, G., Guizard, A. V., Faivre, J., Bouvier, A. M., Carli, P. M., Maynadiã©, M., Danzon, A., Buemi, A., Tretarre, B., Lacour, B., Desandes, E., Colonna, M., Moliniã©, F., Bara, S., Schvartz, C., Ganry, O., Grosclaude, P., Kaatsch, P., Ziegler, H., Tryggvadottir, L., Comber, H., Berrino, F., Allemani, C., Baili, P., Ciampichini, R., Ciccolallo, L., Gatta, G., Micheli, A., Sant, M., Sowe, S., Zigon, G., Tagliabue, G., Contiero, P., Bellã¹, F., Giacomin, A., Ferretti, S., Serraino, D., Dal Maso, L., De Dottori, M., De Paoli, A., Zanier, L., Vercelli, M., Orengo, M. A., Casella, C., Quaglia, A., Pannelli, F., Federico, M., Rashid, I., Cirilli, C., Fusco, M., Traina, A., De Lisi, V., Bozzani, F., Magnani, C., Pastore, G., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Mangone, L., Falcini, F., Foca, F., Giorgetti, S., Senatore, G., Iannelli, A., Budroni, M., Zanetti, R., Patriarca, S., Rosso, S., Piffer, S., Franchini, S., Paci, E., Crocetti, E., La Rosa, F., Stracci, F., Cassetti, T., Zambon, P., Guzzinati, S., Caldora, M., Capocaccia, R., Carrani, E., De Angelis, R., Francisci, S., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Dalmas, M., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Gã³åºdåº, S., Siudowska, U., Mè©zyk, R., Bielska-Lasota, M., Zwierko, M., Pinheiro, P. S., Primic-Žakelj, M., Mateos, A., Izarzugaza, I., Torrella-Ramos, A., Zurriaga, Oscar, Marcos-Gragera, R., Vilardell, M. L., Izquierdo, A., Martinez-Garcia, C., Sã¡nchez, M. J., Navarro, C., Chirlaque, M. D., Peris-Bonet, R., Ardanaz, E., Moreno, C., Galceran, J., Klint, Ã. …., Talbã¤ck, M., Jundt, G., Usel, M., Frick, H., Ess, S. M., Bordoni, A., Luthi, J. C., Konzelmann, I., Probst, N., Lutz, J. M., Pury, P., Visser, O., Otter, R., Schaapveld, M., Coebergh, J. W. W., Janssen-Heijnen, M. L., Van Der Heijden, Louis, Greenberg, D. C., Woods, Laura, Moran, T., Forman, D., Cooper, N., Roche, M., Verne, J., Mã¸ller, H., Meechan, D., Poole, J., Lawrence, G., Stiller, C., Gavin, A., Black, R. J., Brewster, D. H., Steward, J. A., Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Evaluative Epidemiology Unit, Fondazione IRCCS, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Department of Preventive and Predictive Medicine, Unit of Etiological Epidemiology and Prevention, Istituto Nazionale per lo Studio e la Cura dei Tumori, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] (DKFZ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)

Subjects
Gerontology, Male, Cancer Research, MESH: Registries, Survival, MESH : Life Expectancy, MESH : Age Distribution, MESH : Aged, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, MESH: Aged, 80 and over, Neoplasms, 80 and over, Medicine, Cancer registries, MESH: Neoplasms, MESH : Female, 030212 general & internal medicine, Registries, Young adult, MESH: Aged, Aged, 80 and over, MESH: Middle Aged, Relative survival, MESH : Adult, Middle Aged, MESH : Survival Rate, Prognosis, 3. Good health, Europe, Survival Rate, Oncology, MESH: Young Adult, 030220 oncology & carcinogenesis, MESH: Survival Analysis, Cohort, Period Analysis, Female, cancer survival - long term, MESH: Life Expectancy, Adult, MESH: Survival Rate, Period analysis, Adolescent, Age Distribution, Aged, Humans, Life Expectancy, Survival Analysis, Young Adult, MESH : Male, MESH : Europe, MESH : Young Adult, Socio-culturale, [SDV.CAN]Life Sciences [q-bio]/Cancer, 03 medical and health sciences, MESH : Adolescent, MESH : Middle Aged, MESH : Aged, 80 and over, Survival rate, MESH: Age Distribution, Survival analysis, MESH: Adolescent, MESH: Humans, business.industry, MESH : Humans, Cancer, MESH: Adult, medicine.disease, MESH : Neoplasms, MESH: Male, Life expectancy, MESH: Europe, MESH : Survival Analysis, business, MESH: Female, MESH : Registries, Demography
Abstract

International audience; Period analysis has been shown to provide more up-to-date estimates of long-term cancer survival rates than traditional cohort-based analysis. Here, we provide detailed period estimates of 5- and 10-year relative survival by cancer site, country, sex and age for calendar years 2000-2002. In addition, pan-European estimates of 1-, 5- and 10-year relative survival are provided. Overall, survival estimates were mostly higher than previously available cohort estimates. For most cancer sites, survival in countries from Northern Europe, Central Europe and Southern Europe was substantially higher than in the United Kingdom and Ireland and in countries from Eastern Europe. Furthermore, relative survival was also better in female than in male patients and decreased with age for most cancer sites.

Published
2009

18. Influence of morphology on survival for non-Hodgkin lymphoma in Europe and the United States

Author

Sant, Milena, Allemani, Claudia, De Angelis, Roberta, Carbone, Antonino, De SanJose, Silvia, Gianni, Alessandro M., Giraldo, Pilar, Marchesi, Francesca, Marcos-Gragera, Rafael, Martos-Jimenez, Carmen, Maynadie, Marc, Raphael, Martine, Berrino, Franco, Oberaigner, W., Storm, H. H., Aareleid, T., Jechova, M., Rousarova, M., Hakulinen, T., Hedelin, G., Tron, I., Le Gall, E., Launoy, G., MacE-Lesec'h, J., Faivre, J., Chaplain, G., Carli, P. -. M., Danzon, A., Tretarre, B., Colonna, M., Lacour, B., Raverdy, N., Berger, C., Freycon, F., Grosclaude, P., Estãve, J., Kaatsch, P., Ziegler, H., Holzel, D., Schubert Fritschle, G., Tryggvadottir, L., Berrino, F., Allemani, C., Baili, P., Ciccolallo, L., Crosignani, P., Gatta, G., Micheli, A., Sant, M., Ferretti, S., Contil, E., Ramazzotti, V., Vercelli, M., Quaglia, A., Pannelli, F., Federico, M., Artioli, M. E., Ponz De Leon, M., Benatti, P., De Lisi, V., Servente, L., Zanetti, R., Patriarca, S., Magnani, C., Pastore, G., Gafa, L., Tumino, R., Falcini, F., Budroni, M., Paci, E., Crocetti, E., Zambon, P., Guzzinati, S., Capocaccia, R., Carrani, E., De Angelis, R., Roazzi, P., Santaquilani, M., Tavilla, A., Valente, F., Verdecchia, A., Dalmas, M., Langmark, F., Andersen, A., Rachtan, J., Bielska-Lasota, M., Wronkowski, Z., Plesko, I., Obsitnikova, A., Pompe-Kirn, V., Izarzugaza, I., Martinez-Garcia, C., Garau, I., Navarro, C., Chirlaque, M. D., Ardanaz, E., Moreno, C., Galceran, J., Torrella, A., Peris-Bonet, R., Barlow, L., Moller, T., Jundt, G., Lutz, J. M., Usel, M., Coebergh, J. W. W., Van Der Does-Van Den Berg, A., Visser, O., Godward, S., Coleman, M. P., Williams, E. M. I., Forman, D., Quinn, M. J., Roche, M., Edwards, S., Stiller, C., Verne, J., Mã¸ller, H., Bell, J., Botha, J. L., Lawrence, G., Black, R., Steward, J. A., Department of Preventive and Predictive Medicine, Unit of Etiological Epidemiology and Prevention, Istituto Nazionale per lo Studio e la Cura dei Tumori, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Hospital Miguel Servet, Registre des hémopathies malignes de Côte d'Or, Laboratoire d'Hématologie, Université Paris-Sud - Paris 11 ( UP11 ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Bicêtre, Department of Preventive & Predictive Medicine, Fondazione IRCCS-Istituto Nazionale dei Tumori, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Hospital Universitario Miguel Servet, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)

Subjects
Oncology, Cancer Research, Survival, Lymphoma, MESH: Registries, MESH : Age Distribution, MESH : Aged, MESH : Child, Preschool, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, MESH: Aged, 80 and over, MESH: Lymphoma, Non-Hodgkin, MESH : Child, MESH: Child, hemic and lymphatic diseases, 80 and over, Medicine, Registries, Child, Aged, 80 and over, MESH: Aged, MESH: Middle Aged, MESH : Prognosis, Relative survival, Lymphoma, Non-Hodgkin, EUROCARE, Non-Hodgkin's lymphoma, Population cancer registries, US SEER, Adolescent, Adult, Age Distribution, Aged, Child, Preschool, Europe, Feasibility Studies, Humans, Infant, Middle Aged, Prognosis, United States, Absolute risk reduction, MESH : Infant, MESH : Adult, MESH: Infant, 3. Good health, 030220 oncology & carcinogenesis, morphology - survival - non Hodgkin lymphoma - Europe - US, epidemiology, medicine.medical_specialty, MESH : United States, MESH : Feasibility Studies, MESH : Europe, Socio-culturale, Non-Hodgkin, [SDV.CAN]Life Sciences [q-bio]/Cancer, survival, MESH: Prognosis, cancer, 03 medical and health sciences, Internal medicine, MESH : Adolescent, MESH: United States, MESH : Lymphoma, Non-Hodgkin, MESH : Middle Aged, Preschool, MESH : Aged, 80 and over, MESH: Age Distribution, MESH: Adolescent, MESH: Humans, business.industry, MESH: Child, Preschool, MESH : Humans, Cancer, MESH: Adult, medicine.disease, Confidence interval, Cancer registry, Hodgkin lymphoma, MESH: Europe, business, MESH: Feasibility Studies, MESH : Registries, 030215 immunology
Abstract

International audience; We explored the influence of morphology on geographic differences in 5-year survival for non-Hodgkin lymphoma (NHL) diagnosed in 1990-1994 and followed for 5years: 16,955 cases from 27 EUROCARE-3 cancer registries, and 22,713 cases from 9 US SEER registries. Overall 5-year relative survival was 56.1% in EUROCARE west, 47.1% in EUROCARE east and 56.3% in SEER. Relative excess risk (RER) of death was 1.05 (95% confidence interval (CI) 1.01-1.10) in EUROCARE west, 1.52 (95% CI 1.44-1.60) in EUROCARE east (SEER reference). Excess risk of death was significantly above reference (diffuse B lymphoma) for Burkitt's and NOS lymphoma; not different for lymphoblastic and other T-cell; significantly below reference (in the order of decreasing relative excess risk) for NHL NOS, mantle cell/centrocytic, lymphoplasmacytic, follicular, small lymphocytic/chronic lymphocytic leukaemia, other specified NHL and cutaneous morphologies. Interpretation of marked variation in survival with morphology is complicated by classification inconsistencies. The completeness and standardisation of cancer registry morphology data needs to be improved.

Published
2008

19. Trends in cervical cancer survival in Europe, 1983-1994: a population-based study

Author

Bielska-Lasota, M., Inghelmann, R., van de Poll-Franse, L., Capocaccia, R., Storm, H. H., Aareleid, T., Jechova, M., Rousarova, M., Hakulinen, T., Hedelin, G., Tron, I., Le Gall, E., Launoy, G., Mace-Lesec'h, J., Faivre, J., Chaplain, G., Carli, P. -M., Danzon, A., Tretarre, B., Colonna, M., Lacour, B., Raverdy, N., Berger, C., Freycon, B., Grosclaude, P., Esteve, J., Kaatsch, P., Ziegler, H., Holzel, D., Schubert Fritschle, G., Tryggvadottir, L., Berrino, F., Allemani, C., Baili, P., Ciccolallo, L., Crosignani, P., Gatta, G., Micheli, A., Sant, M., Taussig, E., Sowe, S., Ferretti, S., Conti, E., Vercelli, M., Quaglia, A., Pannelli, F., Federico, M., Artioli, M. E., Ponz De Leon, M., Benatti, P., De Lisi, V., Servente, L., Zanetti, R., Patriarca, S., Magnani, C., Pastore, G., Gafa, L., Tumino, R., Falcini, F., Budroni, M., Paci, E., Crocetti, E., Zambon, P., Guzzinati, S., Carrani, E., De Angelis, R., Roazzi, P., Santaquilani, M., Tavilla, A., Valente, F., Verdecchia, A., Dalmas, M., Langmark, F., Andersen, A., Pinheiro, P., Rachtan, J., Wronkowski, Z., Zwierko, M., Plesko, I., Obsitnikova, A., Pompe-Kirn, V., Primic-Zakelj, M., Izarzugaza, I., Martinez-Garcia, C., Garau, I., Navarro, C., Chirlaque, M. D., Ardanaz, E., Moreno, C., Galceran, J., Torrella, A., Peris-Bonet, R., Barlow, L., Moller, T., Jundt, G., Lutz, J. M., Bouchardy, C., Coebergh, J. W. W., van der Does-van den Berg, A., Visser, O., Godward, S., Coleman, M. P., Williams, E. M. I., Forman, D., Quinn, M. J., Roche, M., Edwards, S., Stiller, C., Verne, J., Moller, H., Bell, J., Botha, H., Lawrence, G., Black, R., Steward, J. A., Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)

Subjects
MESH: Registries, MESH : Mortality, MESH : Aged, Uterine Cervical Neoplasms, Disease, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, MESH: Aged, 80 and over, 0302 clinical medicine, MESH : Female, Registries, MESH: Aged, Cervical cancer, Aged, 80 and over, 0303 health sciences, education.field_of_study, MESH: Middle Aged, MESH : Prognosis, Relative survival, Absolute risk reduction, Obstetrics and Gynecology, Middle Aged, MESH : Adult, Prognosis, MESH : Survival Rate, 3. Good health, MESH: Uterine Cervical Neoplasms, Europe, Survival Rate, Oncology, 030220 oncology & carcinogenesis, Adenocarcinoma, Female, Adult, medicine.medical_specialty, MESH: Survival Rate, Adolescent, Population, MESH : Uterine Cervical Neoplasms, MESH : Europe, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH: Prognosis, Trends - cervical cancer - survival, 03 medical and health sciences, MESH : Adolescent, medicine, Humans, MESH : Middle Aged, Mortality, education, MESH : Aged, 80 and over, Survival rate, 030304 developmental biology, Aged, MESH: Adolescent, Gynecology, MESH: Humans, MESH: Mortality, business.industry, MESH : Humans, Cancer, MESH: Adult, Population-based study, Survival, Trends, medicine.disease, MESH: Europe, business, MESH: Female, MESH : Registries, Demography
Abstract

International audience; OBJECTIVE: To evaluate trends in survival from cervical cancer in Europe and in European countries participating in the EUROCARE study as a function of age, morphology and stage at diagnosis. METHODS: Relative survival and relative excess risk of death within 5 years of diagnosis, as a function of age, morphology and stage, among 73,022 women aged 15-99 years diagnosed during 1983-1994 and followed up to 1999 in each of 18 European countries participating in the EUROCARE study, using data from 34 population-based cancer registries. RESULTS: Overall five-year relative survival was 62%, rising by 2% during the period 1983-1994. The highest survival occurred in Northern and Western Europe and the lowest in Central Europe. Survival falls with age at diagnosis, but mainly for localised disease. Survival is higher for adenocarcinoma in younger women, but higher for squamous cell carcinoma in older women. The proportions of younger women, localised cancer and adenocarcinoma all increased. The main improvements in survival were for women under 65, and for metastatic disease. CONCLUSIONS: Survival in Europe has improved slowly but steadily, but the trend is not geographically uniform. Central European countries and the UK saw little or no improvement, and survival in those countries remains the lowest among participating countries in Europe. Further reduction of cervical cancer mortality in Europe may be expected from expansion of screening, and improvement in the treatment of older women, and of metastatic disease.

Published
2007

20. Survival from rare cancer in adults: a population-based study

Author

Gatta, G., Ciccolallo, L., Kunkler, I., Capocaccia, R., Berrino, F., Coleman, M. P., De Angelis, R., Faivre, J., Lutz, J. M., Martinez, C., Möller, T., Sankila, R., Oberaigner, W., Storm, H. H., Aareleid, T., Jechova, M., Rousarova, M., Hakulinen, T., Hédelin, G., Tron, I., Le Gall, E., Launoy, G., Macé Lesec'h, J., Chaplain, G., Carli, P. M., Danzon, A., Tretarre, B., Colonna, M., Lacour, B., Raverdy, N., Berger, C., Freycon, B., Grosclaude, P., Estève, J., Kaatsch, P., Ziegler, H., Hölzel, D., Schubert Fritschle, G., Tryggvadottir, L., Allemani, C., Baili, P., Crosignani, P., Micheli, A., Sant, M., Taussig, E., Sowe, S., Ferretti, S., Conti, E., Vercelli, M., Quaglia, A., Pannelli, F., Federico, Massimo, Artioli, M. E., PONZ DE LEON, Maurizio, Benatti, Piero, De Lisi, V., Servente, L., Zanetti, R., Patriarca, S., Magnani, C., Pastore, G., Gafa, L., Tumino, R., Falcini, F., Budroni, M., Paci, E., Crocetti, E., Zambon, P., Guzzinati, S., Carrani, E., Roazzi, P., Santaquilani, M., Tavilla, A., Valente, F., Verdecchia, A., Dalmas, M., Langmark, F., Andersen, A., Pinheiro, P., Rachtan, J., Bielska Lasota, M., Wronkowski, Z., Zwierko, M., Pleško, I., Obsitníkováa, A., Pompe Kirn, V., Primic Zakelj, M., Izarzugaza, I., Martinez Garcia, C., Garau, I., Navarro, C., Chirlaque, M. D., Ardanaz, E., Moreno, C., Galceran, J., Torrella, A., Peris Bonet, R., Barlow, L., Jundt, G., Bouchardy, C., Coebergh, J. W. W., van der Does van den Berg, A., Visser, O., Godward, S., Williams, E. M. I., Forman, D., Quinn, M. J., Roche, M., Edwards, S., Stiller, C., Verne, J., Møller, H., Bell, J., Botha, H., Lawrence, G., Black, R., Steward, J. A., Evaluative Epidemiology Unit, Fondazione IRCCS, Department of Preventive & Predictive Medicine, Fondazione IRCCS-Istituto Nazionale dei Tumori, Registre Bourguignon des Cancers Digestifs, Lipides - Nutrition - Cancer (U866) ( LNC ), Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon ( ENSBANA ) -Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon ( ENSBANA ) -Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Registre Genevois des Tumeurs, CHU Genève, Service of Preventive Medicine, Hospital Clínico San Carlos, Madrid, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Lipides - Nutrition - Cancer (U866) (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA)-Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA)-Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)

Subjects
Male, Oncology, MESH : Risk, MESH : Aged, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, Neoplasms, Angiosarcoma, MESH: Neoplasms, MESH : Female, MESH: Quality of Health Care, MESH: Aged, 0303 health sciences, MESH: Risk, MESH: Middle Aged, Relative survival, MESH : Quality of Health Care, Rare cancer survival, population-based cancer study, international comparison, Middle Aged, MESH : Adult, 3. Good health, Europe, 030220 oncology & carcinogenesis, MESH: Survival Analysis, MESH : Rare Diseases, Female, Sarcoma, Adult, Risk, MESH: Rare Diseases, medicine.medical_specialty, Adolescent, MESH : Male, MESH : Europe, [SDV.CAN]Life Sciences [q-bio]/Cancer, 03 medical and health sciences, Rare Diseases, Internal medicine, MESH : Adolescent, medicine, Carcinoma, Humans, MESH : Middle Aged, Testicular cancer, Survival analysis, Aged, Quality of Health Care, 030304 developmental biology, MESH: Adolescent, MESH: Humans, Uterine sarcoma, business.industry, MESH : Humans, Cancer, MESH: Adult, medicine.disease, Survival Analysis, MESH : Neoplasms, MESH: Male, MESH: Europe, MESH : Survival Analysis, business, MESH: Female
Abstract

International audience; BACKGROUND: Rare cancers are a challenge to clinical practice, and treatment experience, even in major cancer centres to which rare cancers are usually referred, is often limited. We aimed to study the epidemiology of rare cancers in a large population of several countries. METHODS: We analysed survival by age, sex, subsite, and morphology in 57,144 adults with 14 selected rare cancers diagnosed 1983-94. Variations in survival over time and between European regions were also assessed for variations in quality of care. We also estimated the adjusted relative excess risk of death for every rare cancer. FINDINGS: Overall 5-year relative survival was good (ie, >65%) for placental choriocarcinoma (85.4% [95% CI 81.4-89.5]), thyroid medullary carcinoma (72.4% [69.2-75.5]), ovarian germ-cell cancer (73.0% [70.0-76.0]), lung carcinoid (70.1% [67.3-72.9]), and cervical adenocarcinoma (65.5% [64.3-66.6]); intermediate (ie, 35-65%) for testicular cancer at age 65 years or older (64.0% [59.3-68.7]), sarcoma of extremities (60.0% [58.9-61.2]), digestive-system endocrine cancers (55.6% [54.9-56.3]), anal squamous-cell carcinoma (53.1% [51.5-54.8]), and uterine sarcoma (43.5% [42.0-44.9]); low for carcinoma of adrenal-gland cortex (32.7% [28.3-37.2]) and bladder squamous-cell carcinoma (20.4% [18.8-22.0]); and poor for angiosarcoma of liver (6.4% [1.8-11.0]) and mesothelioma (4.7% [4.3-5.2]). Survival was usually better for women than men and poor in those aged 75 years or older. Survival significantly improved over time for ovarian germ-cell cancer, sarcomas of extremities, digestive-system endocrine tumours, anal squamous-cell carcinoma, and angiosarcoma of liver. Survival in northern Europe was higher than in the other geographic groupings for most cancers. INTERPRETATION: Because effective treatments are available for several of the rare cancers we assessed, further research is needed to ascertain why survival is lower in some European countries than in others, particularly in older patients. Audit of best practice for rare cancers with treatment protocols would be useful.

Published
2006

21. The EUROCARE-3 database: methodology of data collection, standardisation, quality control and statistical analysis

Author

Capocaccia, R., Gatta, G., Roazzi, P., Carrani, E., Santaquilani, M., De Angelis, R., Tavilla, A., Oberaigner, W., Jechova, M., Rousarova, M., Storm, H. H., Aareleid, T., Hakulinen, T., Hédelin, G., Tron, I., Le Gall, E., Launoy, G., Macé Lesech, J., Faivre, J. n. Chaplain G., Carli, P. M., Danzon, A., Tretarre, B., Colonna, M., Lacour, B., Raverdy, N., Berger, C., Freycon, F., Grosclaude, P., Estève, J., Kaatch, P., Ziegler, H., Hölzel, D., Fritschle, G. S., Tryggvadottir, L., Berrino, F., Allemani, C., Baili, P., Ciccolallo, L., Micheli, A., Sant, M., Taussig, E., Hartley, S., Valente, F., Verdecchia, A., Ferretti, S., Crosignani, P., Tagliabue, G., Conti, E., Vercelli, M., Pannelli, F., Vitarelli, S., Mosciatti, P., Federico, Massimo, Artioli, M. E., PONZ DE LEON, Maurizio, Benatti, Piero, De Lisi, V., Serventi, L., Zanetti, R., Patriarca, S., Magnani, C., Pastore, G., Gafà, L., Tumino, R., Falcini, F., Budroni, M., Paci, E., Crocetti, E., Zambon, P., Guzzinati, S., Dalmas, M., Langmark, F., Andersen, A., Rachtan, J., Bielska Lasota, M., Wronkowski, Z., Zwierko, M., Pinheiro, P. S., Pleško, I., Obsitníková, A., Pompe Kim, V., Izarzugaza, I., Martinez Garcia, C., Garau, I., Navarro, C., Chirlaque, M. D., Ardanaz, E., Moreno, C., Galceran, J., Torrella, A., Perisbonet, R., Barlow, L., Möller, T., Jundt, G., Lutz, J. M., Usel, M., Coebergh, J. W. W., Van Der Does Van Den, A., Visser, O., Godward, S., Coleman, M. P., Williams, E. M. I., Forman, D., Quinn, M. J., Roche, M., Edwards, S., Stiller, C., Verne, J., Møller, H., Bell, J., Botha, J. L., Lawrence, G., Black, R., Brewster, D., and Steward, J. A.

Subjects
Adult, Male, Quality Control, computer.software_genre, Stomach Neoplasms, Neoplasms, Autopsy Only, Cancer survival, Data quality, Population-based cancer registries, standardisation - quality control - statistical analysis, medicine, Humans, Statistical analysis, Registries, Medical diagnosis, Stage (cooking), Child, cancer survival, methodology - data collection, Data collection, Database, Relative survival, business.industry, Data Collection, Age Factors, Cancer, Hematology, medicine.disease, Survival Analysis, Europe, Survival Rate, Databases as Topic, Oncology, Data quality, Female, Colorectal Neoplasms, business, computer
Abstract

The EUROCARE database contains data on 6.5 million cancer patients diagnosed from 1978 to 1994 in populations covered by 67 cancer registries in 22 European countries. The quality-checked entries specify age, sex, diagnosis date, cancer site, morphology, microscopic confirmation and vital status, as well as containing broad indicators of stage. For EUROCARE-3, which refers to diagnoses from 1990 to 1994, 3389 cases with major data problems and 142,525 second or subsequent cancers were removed, leaving more than 2 million cases for analysis. From these data, observed and relative survival for each cancer site and country were calculated at 1, 3 and 5 years from diagnosis. Overall European survival for each cancer site and for all cancers combined were calculated combining country-specific survival figures. Overall, 1.1% of cases were lost to follow-up, 4.2% were known from death certificates only and 1.2% were known at autopsy only. The percentage of microscopically confirmed cases varied with cancer site and country, and was always higher in northern European countries. Comparison of quality indicators for the EUROCARE-3 database with earlier EUROCARE databases indicates that data quality and standardisation have improved.

Published
2003

22. Scrotal cancer: incidence, survival and second primary tumours in the Netherlands since 1989.

Author

Verhoeven, R. H. A., Louwman, W. J., Koldewijn, E. L., Demeyere, T. B. J., and Coebergh, J. W. W.

Subjects
SCROTUM, EPIDEMIOLOGY, DISEASE incidence, HISTOLOGY, BASAL cell carcinoma, PUBLIC health, CANCER
Abstract

Background: Since the 1970s there have been few epidemiological studies of scrotal cancer. We report on the descriptive epidemiology of scrotal cancer in the Netherlands.Methods: Data on all scrotal cancer patients were obtained from the Netherlands Cancer Registry (NCR) in the period 1989-2006 and age-standardised incidence rates were calculated also according to histology and stage. Relative survival was calculated and multiple primary tumours were studied.Results: The overall incidence rate varied around 1.5 per 1,000,000 person-years, most frequently being squamous cell carcinoma (27%), basal cell carcinoma (19%) and Bowen's disease (15%). Overall 5-year relative survival was 82%, being 77% and 95% for patients with squamous and basal cell carcinoma, respectively. In all, 18% of the patients were diagnosed with a second primary tumour.Conclusion: The incidence rate of scrotal cancer did not decrease, although this was expected; affected patients might benefit from regular checkups for possible new cancers. [ABSTRACT FROM AUTHOR]

Published
2010
Full Text
View/download PDF

23. Trends in the incidence of adenocarcinoma of the oesophagus and cardia in the Netherlands 1989–2003.

Author

van Blankenstein, M., Looman, C. W. N., Siersema, P. D., Kuipers, E. J., and Coebergh, J. W. W.

Subjects
ADENOCARCINOMA, CANCER, TUMORS, ADENOID cystic carcinoma
Abstract

Over the 15-year period 1989–2003, the incidence of oesophagus–cardia adenocarcinoma in the Netherlands rose annually by 2.6% for males and 1.2% for females. This was the net outcome of annual increases in the incidence of adenocarcinoma of the oesophagus (ACO) of 7.2% for males and 3.5% for females and annual declines in the incidence of adenocarcinoma of the gastric cardia (AGC) of more than 1% for both genders. Nonlinear cohort patterns were found in females with ACO and for both genders in AGC; a nonlinear period pattern was observed only in males with AGC. These differing epidemiological patterns for ACO and AGC do not support a common aetiology. Proposed underlying factors for the rise in ACO incidence appear to have little effect on AGC incidence. This and the secular decline in smoking among males may have led to the decline in AGC incidence.British Journal of Cancer (2007) 96, 1767–1771. doi:10.1038/sj.bjc.6603798 www.bjcancer.com Published online 15 May 2007 [ABSTRACT FROM AUTHOR]

Published
2007
Full Text
View/download PDF

24. Increased risk of second malignancies after in situ breast carcinoma in a population-based registry.

Author

Soerjomataram, I., Louwman, W. J., van der Sangen, M. J. C., Roumen, R. M. H., and Coebergh, J. W. W.

Subjects
BREAST cancer, BREAST cancer patients, CANCER, CANCER risk factors
Abstract

Among 1276 primary breast carcinoma in situ (BCIS) patients diagnosed in 1972-2002 in the Southern Netherlands, 11% developed a second cancer. Breast carcinoma in situ patients exhibited a two-fold increased risk of second cancer (standardised incidence ratios (SIR): 2.1, 95% confidence interval (CI): 1.7-2.5). The risk was highest for a second breast cancer (SIR: 3.4, 95% CI: 2.6-4.3; AER: 66 patients per 10,000 per year) followed by skin cancer (SIR: 1.7, 95% CI: 1.1-2.6; AER: 17 patients per 10,000 per year). The increased risk of second breast cancer was similar for the ipsilateral (SIR: 1.9, 95% CI: 1.3-2.7) and contralateral (SIR: 2.0, 95% CI: 1.4-2.8) breast. Risk of second cancer was independent of age at diagnosis, type of initial therapy, histologic type of BCIS and period of diagnosis. Standardised incidence ratios of second cancer after BCIS (SIR: 2.3, 95% CI: 1.8-2.8) resembled that after invasive breast cancer (SIR: 2.2, 95% CI: 2.1-2.4). Surveillance should be directed towards second (ipsi- and contra-lateral) breast cancer. [ABSTRACT FROM AUTHOR]

Published
2006
Full Text
View/download PDF

25. Added value of three-way methods for the analysis of mortality trends illustrated with worldwide female cancer mortality (1968-1985).

Author

Kroonenberg, PM, Murakami, T, Coebergh, JWW, Kroonenberg, P M, and Coebergh, J W W

Subjects
CANCER, DISEASES in women
Abstract

Trends in mortality rates are usually presented per tumour site or per country without an overall analysis of the complete data encompassing all three aspects (tumour sites, countries, trends). This paper presents a methodology for such an overall analysis using three-way methods applied to a data set on female mortality rates for 17 tumour sites of 43 countries for the years 1968-1985. Multivariate techniques like biplots and three-mode principal component analysis within an overall three-way analysis-of-variance framework were used. We confirmed the known patterns of comparatively high mortality for women due to cancer of the bladder, intestines, pancreas, rectum, breast, ovary, skin and leukaemia and the relatively low mortality rates for liver cancer in Western and Northern Europe, the USA, Australia and New Zealand. Also, the reverse pattern was observed for Middle and Southern Europe, Hong Kong, Singapore, and in Japan, and in some but not all Latin American countries. The relatively mortality due to cancer was high in the lungs, mouth, larynx and oesophagus in the British Isles, but was much less in other European countries. Mortality due to cancer of the thyroid, uterus, gall bladder and stomach was high in Middle European countries, as was the case in Japan, Chile and Costa Rica. Rates were low for Southern European countries, North America, Australia and New Zealand. Specific deviating patterns in the data were the more rapidly decreasing mortality rates for stomach cancer in Chile and Japan and the more rapidly increasing mortality rates for lung cancer in the USA, Scotland and Denmark. In conclusion, using three-way methods, it was feasible to analyse the cancer mortality data in their entirety. This enabled the simultaneous comparison of trends in relative mortality rates between all countries due to all tumour sites, as well as the identification of specific deviating trends for specific tumour sites in specific countries. [ABSTRACT FROM AUTHOR]

Published
2002
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results